Treatments for hepatitis B

被引：15

作者：

Asmuth, DM ^{[1
]}

Nguyen, HH ^{[1
]}

Melcher, GP ^{[1
]}

Cohen, SH ^{[1
]}

Pollard, RB ^{[1
]}

机构：

[1] Univ Calif Davis, Med Ctr, Dept Internal Med, Div Infect Dis, Sacramento, CA 95817 USA

来源：

CLINICAL INFECTIOUS DISEASES | 2004年 / 39卷 / 09期

关键词：

D O I：

10.1086/425010

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

New optimism surrounds treatments for chronic hepatitis B (CHB). Interferon-alpha, lamivudine, and adefovir dipivoxil are currently approved by the United States Food and Drug Administration for the treatment of CHB. All 3 treatments possess unique characteristics with respect to their side effect profiles, potencies, and treatment niches within the spectrum of CHB. New agents, which are in various stages of clinical development, represent potential improvements within existing, as well as novel, classes of antiviral therapy, and they offer significant promise of a cure for the many patients with chronic and progressive hepatitis B. However, there remain many challenges in understanding the implications of drug resistance, the role of combination therapy, and how to define the response to therapy within subsets of patients with hepatitis B.

引用

页码：1353 / 1362

页数：10

共 121 条

[1] The relationship between simian immunodeficiency virus RNA levels and the mRNA levels of alpha/beta interferons (IFN-α/β) and IFN-α/β-inducible Mx in lymphoid tissues of rhesus macaques during acute and chronic infection [J].

Abel, K ;

Alegria-Hartman, MJ ;

Rothaeusler, K ;

Marthas, M ;

Miller, CJ .

JOURNAL OF VIROLOGY, 2002, 76 (16) :8433-8445

[2] Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase [J].

Angus, P ;

Vaughan, R ;

Xiong, S ;

Yang, HL ;

Delaney, W ;

Gibbs, C ;

Brosgart, C ;

Colledge, D ;

Edwards, R ;

Ayres, A ;

Bartholomeusz, A ;

Locarnini, S .

GASTROENTEROLOGY, 2003, 125 (02) :292-297

[3] Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial [J].

Barbaro, G ;

Zechini, F ;

Pellicelli, AM ;

Francavilla, R ;

Scotto, G ;

Bacca, D ;

Bruno, M ;

Babudieri, S ;

Annese, M ;

Matarazzo, F ;

Di Stefano, G ;

Barbarini, G .

JOURNAL OF HEPATOLOGY, 2001, 35 (03) :406-411

[4]

Baron S, 1980, Ann N Y Acad Sci, V350, P130, DOI 10.1111/j.1749-6632.1980.tb20614.x

[5] Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation [J].

Bartholomew, MM ;

Jansen, RW ;

Jeffers, LJ ;

Reddy, KR ;

Johnson, LC ;

Bunzendahl, H ;

Condreay, LD ;

Tzakis, AG ;

Schiff, ER ;

Brown, NA .

LANCET, 1997, 349 (9044) :20-22

[6] Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study [J].

Benhamou, Y ;

Bochet, M ;

Thibault, V ;

Calvez, V ;

Fievet, MH ;

Vig, P ;

Gibbs, CS ;

Brosgart, C ;

Fry, J ;

Namini, H ;

Katiama, C ;

Poynard, T .

LANCET, 2001, 358 (9283) :718-723

[7] Role of hepatitis B virus specific cytotoxic T cells in liver damage and viral control [J].

Bertoletti, A ;

Maini, M ;

Williams, R .

ANTIVIRAL RESEARCH, 2003, 60 (02) :61-66

[8] Protection or damage: a dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C infection? [J].

Bertoletti, A ;

Maini, MK .

CURRENT OPINION IN IMMUNOLOGY, 2000, 12 (04) :403-408

[9] Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine [J].

Bessesen, M ;

Ives, D ;

Condreay, L ;

Lawrence, S ;

Sherman, KE .

CLINICAL INFECTIOUS DISEASES, 1999, 28 (05) :1032-1035

[10] Role of early cytokines, including alpha and beta interferons (IFN-α/β), in innate and adaptive immune responses to viral infections [J].

Biron, CA .

SEMINARS IN IMMUNOLOGY, 1998, 10 (05) :383-390

← 1 2 3 4 5 6 7 8 9 10 →